trending Market Intelligence /marketintelligence/en/news-insights/trending/iaawoutp9-vy6rbp82f6pw2 content esgSubNav
In This List

Mylan's generic version of Pfizer birth control injection wins US FDA approval

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Mylan's generic version of Pfizer birth control injection wins US FDA approval

The U.S. Food and Drug Administration approved Mylan NV's generic version of Pfizer Inc.'s birth control injection Depo-Provera.

Mylan is offering the hormonal contraceptive medroxyprogesterone acetate in single-dose vials.

Sales of the drug in the U.S. were about $181 million for the year ending July 31, the company said in an Oct. 18 news release, citing IQVIA data.

Mylan develops and markets generic, brand-name and over-the-counter products worldwide.